Next Article in Journal
Nox Gene Expression and Cytochemical Localization of Hydrogen Peroxide in Polyporus umbellatus Sclerotial Formation
Next Article in Special Issue
p27 Is a Critical Prognostic Biomarker in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Previous Article in Journal
New Insights into Functional Roles of the Polypyrimidine Tract-Binding Protein
Previous Article in Special Issue
Environmental Pollution: A Tangible Risk for NAFLD Pathogenesis
Open AccessReview

Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment

Endocrinology, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro 88100, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2013, 14(11), 22933-22966; https://doi.org/10.3390/ijms141122933
Received: 1 October 2013 / Revised: 30 October 2013 / Accepted: 8 November 2013 / Published: 20 November 2013
(This article belongs to the Special Issue Non-Alcoholic Fatty Liver Disease Research)
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Several lines of evidence have indicated a pathogenic role of insulin resistance, and a strong association with type 2 diabetes (T2MD) and metabolic syndrome. Importantly, NAFLD appears to enhance the risk for T2MD, as well as worsen glycemic control and cardiovascular disease in diabetic patients. In turn, T2MD may promote NAFLD progression. The opportunity to take into account NAFLD in T2MD prevention and care has stimulated several clinical studies in which antidiabetic drugs, such as metformin, thiazolidinediones, GLP-1 analogues and DPP-4 inhibitors have been evaluated in NAFLD patients. In this review, we provide an overview of preclinical and clinical evidences on the possible efficacy of antidiabetic drugs in NAFLD treatment. Overall, available data suggest that metformin has beneficial effects on body weight reduction and metabolic parameters, with uncertain effects on liver histology, while pioglitazone may improve liver histology. Few data, mostly preclinical, are available on DPP4 inhibitors and GLP-1 analogues. The heterogeneity of these studies and the small number of patients do not allow for firm conclusions about treatment guidelines, and further randomized, controlled studies are needed. View Full-Text
Keywords: nonalcoholic fatty liver disease (NAFLD); insulin resistance; type 2 diabetes mellitus (T2DM); cardiovascular disease (CVD); antidiabetic drugs; statins nonalcoholic fatty liver disease (NAFLD); insulin resistance; type 2 diabetes mellitus (T2DM); cardiovascular disease (CVD); antidiabetic drugs; statins
MDPI and ACS Style

Fruci, B.; Giuliano, S.; Mazza, A.; Malaguarnera, R.; Belfiore, A. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. Int. J. Mol. Sci. 2013, 14, 22933-22966.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop